Summary: Biogen, Eisai, and Eli Lilly’s Alzheimer’s drugs have shown little efficacy, particularly in non-APOE4
Summary: Eli Lilly and Company’s share price won’t stop climbing on the promise of its
Summary: The clinical trial was able to demonstrate a slowing of disease progression, but it’s
Summary: Alzheimer’s drug is expected to receive full approval. Mounjaro formulary placement may fuel sales
Summary: Eli Lilly has seen a massive ramp-up in its diabetes, or better said weight
Summary: Eli Lilly’s well-diversified portfolio and pipeline have been rewarded by the market, with its
Summary: Eli Lilly and Company continues to make impressive progress when it comes to its
Summary: This week Lilly surpassed Johnson & Johnson to become the world’s largest Pharma by
Summary: Eli Lilly reported an 11% decrease in worldwide revenue for Q1 2023, largely due
Summary: Like other anti-amyloid drugs, Eli Lilly’s donanemab does not help APOE4 non-carriers. Donanemab does